HPLC Method for Analysis of Guanylurea, Metformin on Primesep 100 by SIELC Technologies

Guanylurea is a known degradation product of metformin with the formula C₂H₆N₄O. When metformin undergoes biotransformation in the body, one of the metabolic pathways leads to the formation of guanylurea. This process is a part of the pharmacokinetics of metformin, where the drug is metabolized and eventually excreted from the body.

The conversion of metformin to guanylurea is significant for a few reasons:

Pharmacokinetics: Understanding the metabolism of metformin, including its conversion to guanylurea, is important for comprehending its action in the body, its elimination, and any potential metabolite-related effects.

Environmental Impact: The presence of pharmaceuticals and their metabolites, like guanylurea from metformin, in the environment (especially in water sources) has become a topic of environmental concern. This is because these compounds can have effects on aquatic life and potentially re-enter the human water supply.

Safety and Efficacy: Knowing the metabolites of a drug helps in assessing its safety and efficacy. While guanylurea is not known to have significant pharmacological effects in the context of metformin’s use as a diabetes medication, its identification is essential for a complete understanding of the drug’s profile.

Guanylurea, Metformin can be retained, separated and analyzed on a Primesep 100 mixed-mode stationary phase column using an analytical method with a simple mobile phase of water, Acetonitrile (MeCN), and a sulfuric acid as a buffer. This analysis method can be detected using UV at 200 nm.